Pancreatic cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• KRAS 67
• PD-1 39
• TP53 4
• mTOR 0
• PI3K 0
• STAT3 0
• PD-L1 20
• CLDN18 21
• EGFR 11
• RAS 17
• BRCA2 8
• AKT 0
• BRCA1 10
• ERK 0
• MAPK 1
• PARP 9
• STING 0
• HER2 13
• MYC 0
• YAP 0
• MEK 5
• PALB2 9
• CTLA-4 9
• VEGF 3
• AMPK 0
• ATM 3
• CD40 2
• CXCR4 0
• HIF-1 0
• JNK 0
• NRF2 0
• CDKN2A 3
• GLP-1 2
• NRAS 5
• PRMT5 6
• IL-6 0
• PPAR 0
• PTEN 0
• BCL-2 0
• FAK 1
• IL-15 1
• JAK 0
• TROP2 3
• BRAF 2
• MET 2
• B7-H3 2
• CDK4/6 0
• CTNNB1 0
• FGFR 1
• HSP90 0
• HDAC 0
• KEAP1 1
• CD47 0
• METTL3 0
• MUC1 3
• AXL 1
• CCR5 0
• HER3 1
• HMGB1 1
• NTRK 1

24 of 27+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · F31

  Assessing autophagic dependencies in the context of RAS inhibition in pancreatic ductal adenocarcinoma

  Univ of North Carolina Chapel Hill· Chapel Hill, United States· US$37,011 awarded in fiscal year 2026· until Sept 2029

• FDA · R01

  Safety and Efficacy of a Multi-Tumor-Associated Antigen-Specific T Cell Therapy in Pancreatic Cancer Patients

  Marker Therapeutics, Inc.· Houston, United States· US$645,493 awarded in fiscal year 2026· until Aug 2030

• NIH NIAMS · R21

  Nuclear Receptors In Cancer Cachexia

  University of Texas Hlth Sci Ctr Houston· Houston, United States· US$200,604 awarded in fiscal year 2026· until Jul 2028

• NIH NCI · U01

  The role of circadian gene regulation in pancreatic cancer progression and immune evasion

  University of Rochester· Rochester, United States· US$626,555 awarded in fiscal year 2026· until Aug 2031

• NIH NIAMS · R56

  Mitochondrial permeability transition in cancer cachexia

  University of Florida· Gainesville, United States· US$307,000 awarded in fiscal year 2026· until Aug 2027

• European Commission (Horizon Europe) · HORIZON-ERC

  Immunity under Pressure: Mapping Compression Driven Tumor–Immune Rewiring to Potentiate Immunotherapy in Pancreatic Cancer (MechanoImmunoMap)

  University of Cyprus· Nicosia, Cyprus· EU contribution €1,500,000· until Jan 2032

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Glycoengineering for Immune Modulation in Precision Anti-Cancer Therapies (GlycoIMPACT)

  Universitat Wien· Wien, Austria· EU contribution €230,185· until Dec 2028· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Next-Generation Radiopharmaceuticals for Glioblastoma and Pancreatic Cancer: A 3D Perspective (radio3D)

  Agencia Estatal Consejo Superior de Investigaciones Cientificas· Madrid, Spain· EU contribution €4,366,500· until Dec 2030· 9 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  Evoking anti-tumor immunity in pancreatic cancer (Evoke-PDAC)

  Deutsches Krebsforschungszentrum Heidelberg· Heidelberg, Germany· EU contribution €2,497,125· until Dec 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  EXPLORING THE MECHANISM OF METASTASIS/DEVELOPMENT OF NEW TESTS TO ENROLL CIRCULATING TUMOR CELLS (CTCs) INTO CLINICAL PRACTICE (CTC4CLINIC)

  Panepistimio Patron· Rio Patras, Greece· EU contribution €796,590· until Dec 2030· 7 countries

10 of 864 running projects, newest first. Listed amounts together: US$468.4m + €177.8m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Study of IK-595 in RAS- or RAF-altered Advanced Tumors

  NCT06270082· Ikena Oncology· Updated 19 Sept 2025

  “Limited resources and strategic priorities”Registry text, quoted unchanged. Source

• Terminated

  A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers

  NCT06194877· MapKure, LLC· Updated 20 Apr 2025

  “Funding terminated due to business reasons”Registry text, quoted unchanged. Source

• Withdrawn

  Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer

  NCT04870034· Roswell Park Cancer Institute· Updated 22 Dec 2023

  “Issues recruiting”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

  NCT03190941· National Cancer Institute (NCI)· Source

• Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial

  NCT05554367· National Cancer Institute (NCI)· Source

• A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers

  NCT06194877· MapKure, LLC· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 50
• Organoids 47
• Mendelian Randomization Analysis 29
• CRISPR-Cas Systems 16
• Gene Expression Profiling 123
• Sequence Analysis, RNA 11
• Whole Genome Sequencing 3
• Exome Sequencing 10
• Proteomics 55
• Metabolomics 34
• Mass Spectrometry 10
• Flow Cytometry 32
• Immunohistochemistry 70
• Liquid Biopsy 30
• Circulating Tumor DNA 29
• Xenograft Model Antitumor Assays 300
• Positron-Emission Tomography 30
• Magnetic Resonance Imaging 117
• Machine Learning 58
• Deep Learning 55
• Cohort Studies 108
• Genome-Wide Association Study 24

• Primer exchange reaction-based dual-signal amplified nano-flow cytometry and fluorescence analysis of MUC1- positive exosomes.

  Talanta, Jul 2026

• High-quality acinar cell isolation enables single-cell analysis of healthy and injured pancreas.

  Cell Rep Methods, Apr 2026

• Assessment of NK cell cytotoxicity induced by IL-15 based immunotherapy against cancer cells.

  Methods Cell Biol, Apr 2026

• Single-cell RNA sequencing and high-dimensional flow cytometry reveal distinct peripheral immune landscapes of type 1 autoimmune pancreatitis and pancreatic ductal adenocarcinoma.

  Clin Transl Med, Apr 2026

• Protocol for analyzing immune cell infiltration in 3D pancreatic heterotypic spheroids composed of tumor cells and cancer-associated fibroblasts.

  STAR Protoc, Feb 2026

• Integrated single cell RNA sequencing and flow cytometry analysis identifies elevated S100A6+ and S100A8+ myeloid subsets in pancreatic ductal adenocarcinoma.

  Clin Immunol, Jan 2026

• Single-Cell RNA Sequencing of Pancreatic Circulating Tumor Cells.

  Methods Mol Biol, Jan 2026

• Bone Marrow Metastasis from a Pancreatic Neuroendocrine Tumor: Morphologic Mimicry of Acute Leukemia.

  Clin Lab, Dec 2025

• Investigation of the synergistic effect of metformin and FX11 on PANC-1 cell lines.

  Biol Res, Mar 2025

• Classical and atypical resistance of cancer cells as a target for resveratrol.

  Oncol Rep, Jul 2016

See which targets of this disease your abstract mentions, and go to the people working on them.